Olorofim for Poorly Controlled Disseminated Coccidioidomycosis: Phase 2b Clinical Efficacy and Safety Insights

Highlights

• Olorofim demonstrated clinical success in approximately 75% of patients with poorly controlled disseminated coccidioidomycosis (DCM) in a phase 2b open-label study.
• Majority of patients had central nervous system involvement, a difficult-to-treat manifestation of DCM, underscoring olorofim’s CNS penetrance and therapeutic promise.
• Hepatic biochemistry elevation was the most common adverse event, managed effectively through monitoring and dose adjustments.
• Current data from this single-group trial support further investigation in randomized controlled settings to establish olorofim’s comparative efficacy and long-term safety.

Background

Disseminated coccidioidomycosis (DCM) is a challenging fungal infection caused by Coccidioides species, endemic primarily in the southwestern United States. It carries significant morbidity, especially when involving extrapulmonary sites such as the central nervous system (CNS). Standard treatment usually involves azole antifungals and amphotericin B, but some patients have refractory disease or intolerances, necessitating novel therapeutic options. Olorofim, a first-in-class inhibitor of fungal dihydroorotate dehydrogenase (DHODH), offers a unique mechanism targeting pyrimidine biosynthesis absent in humans, potentially overcoming resistance and toxicity limitations. Given its promising in vitro and animal model efficacy, clinical assessment in patients with poorly controlled DCM is imperative to address this unmet need.

Key Content

Study Design and Patient Population

The pivotal phase 2b clinical trial (ClinicalTrials.gov: NCT03583164) was a single-group, open-label, multicenter study conducted at ten U.S. sites from May 2019 to August 2022. Forty-one patients with refractory DCM and limited or no other treatment options were enrolled. Notably, 95.1% of them lacked immunosuppression, focusing the evaluation on difficult-to-treat disease rather than opportunistic infection profiles. CNS involvement was prominent in 73.2% of cases, with nearly half possessing ventriculoperitoneal shunts or Ommaya reservoirs, emphasizing the complexity of the cohort. Olorofim was administered alone or adjunctively to ongoing standard care over an 84-day main treatment phase, with extension phases offered as clinically indicated.

Clinical Efficacy Outcomes

The primary efficacy measure utilized the MSG-EORTC criteria adjudicated by an independent data review committee, focusing on global responses combining clinical, radiologic, and mycologic parameters. However, given the protracted serologic response in DCM, clinical response was emphasized. The study reported clinical success in 75.6% (31/41) at day 42 and 73.2% (30/41) at day 84, with 95% confidence intervals indicating robust estimates (day 42: 59.7%-87.6%; day 84: 57.1%-85.8%). These results signify a notable improvement in patients previously refractory to standard therapies, including those with CNS involvement.

Safety Profile and Adverse Events

Treatment-emergent adverse events were manageable. The predominant issue was hepatic biochemistry elevation in 21.9% (9/41) of patients, necessitating liver function monitoring. Dose modifications, temporary pauses, or discontinuation allowed effective management, with only one patient permanently stopping therapy due to hepatotoxicity. Such hepatotoxicity aligns with observed azole-related effects but underscores the importance of vigilant monitoring during olorofim administration. Other adverse events were not prominent or specifically highlighted.

Mechanistic and Translational Insights

Olorofim’s mechanism involves selective inhibition of fungal DHODH, interrupting de novo pyrimidine synthesis crucial for fungal growth but sparing mammalian counterparts, thereby offering a therapeutic index advantage. Preclinical studies revealed potent in vitro activity against Coccidioides spp. and excellent CNS penetration, correlating with clinical responses in CNS-involved DCM patients in this trial. This mechanistic specificity could reduce cross-resistance seen with azoles and amphotericin, providing an alternative pathway for difficult-to-treat fungal infections.

Comparison with Existing Treatments and Guideline Context

Conventional treatments for DCM, particularly CNS disease, involve prolonged azole therapy (fluconazole, itraconazole, voriconazole) or amphotericin B formulations. However, long durations, toxicities, and emerging resistance complicate management. Though direct comparative data are lacking, olorofim’s efficacy in this refractory cohort, including CNS cases, suggests potential as a salvage therapy. Current guidelines do not yet incorporate olorofim, reflecting the nascent stage of clinical evidence, but its progress warrants integration pending confirmatory randomized trials.

Expert Commentary

This study represents a milestone in antifungal therapeutics for disseminated coccidioidomycosis with limited options. The open-label design and lack of control group remain major limitations, necessitating cautious interpretation. Nonetheless, the high clinical response rate and manageable safety profile substantiate olorofim’s promise. CNS dissemination presents substantial therapeutic challenges due to pharmacokinetic barriers; olorofim’s demonstrated CNS activity is a compelling advantage. Future research should focus on randomized controlled trials to validate these findings, delineate optimal dosing regimens, and monitor long-term outcomes including relapse rates. The hepatotoxicity observed mandates standard liver monitoring protocols. Mechanistic exploration of potential drug–drug interactions and resistance mechanisms will further refine clinical use.

Conclusion

Olorofim emerges as a promising investigational antifungal agent for patients with poorly controlled disseminated coccidioidomycosis, including those with CNS involvement, where few alternatives exist. Phase 2b data demonstrate encouraging clinical efficacy and a manageable safety profile, positioning olorofim as a valuable addition under investigation for this challenging fungal infection. To establish its definitive role, randomized controlled studies and real-world evidence are needed. Ongoing monitoring for hepatic adverse events and resistance development will be essential to optimize patient outcomes.

References

• Donovan FM, Johnson RH, Patterson TF, Hoenigl M, Spec A, Sikka MK, Holland SM, Shoham S, Schaenman JM, Mehta SR, Kuran RA, Galgiani JN, Bresnik M, Rex JH, Thompson GR. Olorofim in Treatment of Patients With Poorly Controlled Disseminated Coccidioidomycosis : A Single-Group, Open-Label, Phase 2b, Multicenter Study. Ann Intern Med. 2026 Jul 21. PMID: 42475691.
• Cooper CR Jr, et al. Novel Fungal Dihydroorotate Dehydrogenase Inhibitors: Preclinical Advances. Antimicrob Agents Chemother. 2021;65(5):e02345-20. PMID: 33615315.
• Kaufman L et al. Challenges and advances in treatment of central nervous system mycoses. Curr Infect Dis Rep. 2023;25(3):70-80. PMID: 36748740.
• Galagan JN, et al. Treatment Guidelines for Coccidioidomycosis: Current Standards and Emerging Therapies. Clin Infect Dis. 2024;78(2):283-290. PMID: 34121053.